Acquired Company

Tottenham Acquisition I Limited completed its merger with Clene Nanomedicine, Inc., and the combined company began trading as Clene Inc. on the Nasdaq under the ticker CLNN starting December 31, 2020 (closing date December 30, 2020).

Clene Inc. is a clinical-stage biopharmaceutical company based in Salt Lake City, Utah, dedicated to pioneering clean-surface nanotechnology (CSN) therapies targeting neurodegenerative diseases and other significant health challenges. The company is currently navigating advanced clinical trials to substantiate the safety and efficacy of its innovative product pipeline, positioning itself as a potential leader in the biopharmaceutical sector. With a strong scientific foundation and a clear focus on transformative healthcare solutions, Clene offers a compelling investment opportunity for institutional investors seeking to support impactful medical advancements. Show more

Location: 6550 SOUTH MILLROCK DRIVE, SALT LAKE CITY, UT, UNITED STATES, 84121, Salt Lake City, UT, 84121, USA | Website: https://clene.com | Industry: PACKAGED FOODS | Sector: CONSUMER DEFENSIVE

Market Cap

48.17M

52 Wk Range

$2.28 - $13.50

Previous Close

$4.17

Open

$4.42

Volume

63,763

Day Range

$4.06 - $4.42

Enterprise Value

62.5M

Cash

7.925M

Avg Qtr Burn

-3.975M

Insider Ownership

28.62%

Institutional Own.

17.32%

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
CNM-Au8 Details Amyotrophic lateral sclerosis	NDA Submission	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CNM-Au8 Details Multiple sclerosis	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CNM-Au8 Details Multiple sclerosis	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CNM-Au8 Details Amyotrophic lateral sclerosis	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CNM-ZnAg Details COVID-19	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CNM-Au8 Details Parkinson's disease	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.